Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.59 USD | +0.07% | +0.21% | +8.61% |
May. 16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
May. 16 | Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.61% | 3.45B | |
+10.37% | 126B | |
-5.47% | 11.3B | |
+4.83% | 9.16B | |
+36.53% | 5.46B | |
-25.10% | 4.53B | |
-10.05% | 2.76B | |
-10.99% | 2.09B | |
-10.20% | 2B | |
-23.65% | 1.77B |
- Stock Market
- Equities
- AXNX Stock
- News Axonics, Inc.
- Nephron Research Downgrades Axonics to Hold From Buy, Raises Price Target to $71 From $65